Free Trial
→ Dalio heeds Buffett’s warning… [$319 million stake in gold] (From Golden Portfolio) (Ad)
NASDAQ:SNPX

Synaptogenix 11/14/2023 Earnings Report

Synaptogenix logo
$2.46 -0.04 (-1.60%)
Closing price 05/30/2025 03:59 PM Eastern
Extended Trading
$2.57 +0.11 (+4.47%)
As of 05/30/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Synaptogenix EPS Results

Actual EPS
-$0.75
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Synaptogenix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Synaptogenix Announcement Details

Quarter
Date
11/14/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Synaptogenix Earnings Headlines

Synaptogenix (NASDAQ:SNPX) Trading 1.5% Higher - Here's What Happened
May 28, 2025 | americanbankingnews.com
Synaptogenix Inc Ordinary Shares
January 3, 2025 | morningstar.com
The “black glass” breakthrough behind AI’s next leap
AI is advancing fast… But there’s one problem almost no one’s talking about. Power.
June 1, 2025 | True Market Insiders (Ad)
Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength
December 20, 2024 | prnewswire.com
Synaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News Summary
October 7, 2024 | benzinga.com
Synaptogenix secures $5 million in preferred stock financing
September 13, 2024 | investing.com
See More Synaptogenix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synaptogenix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synaptogenix and other key companies, straight to your email.

About Synaptogenix

Synaptogenix (NASDAQ:SNPX) operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

View Synaptogenix Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles